Why Is CAPR Stock Rising Today? Piper Sandler Says Risk-Reward Favors Owning Stock Into FDA Decision
Piper Sandler upgraded Capricor to ‘Overweight’ from ‘Neutral’ and sharply raised the price target to $25, a roughly 150% upside potential from current levels. The brokerage believes the risk-reward favors the stock heading into FDA’s decision in November. Last week, the FDA extended the review deadline for Capricor’s Deramiocel to Nov. 22, 2026. CAPR shares … Read more